# Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants

> **NCT06912295** · PHASE1 · RECRUITING · sponsor: **Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.** · enrollment: 76 (estimated)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** HL-1186
- **DRUG:** HL-1186 placebo

## Key facts

- **NCT ID:** NCT06912295
- **Lead sponsor:** Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-21
- **Primary completion:** 2025-08-30
- **Final completion:** 2025-10-09
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2025-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06912295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06912295, "Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06912295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*